Sign In
Buy HQL
$18.63
+0.290 (+1.58%)
At Close: Jun 23, 2026
How To Protect Your Wealth, Grab 7%+ Dividends, In This Pullback
06:10pm, Tuesday, 01'st Mar 2022
You can be forgiven if your stomach tightens just a bit when you go to check your retirement account.
Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend
05:05am, Friday, 11'th Feb 2022
HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive.
5 Closed-End Funds Bought In November
04:27pm, Tuesday, 14'th Dec 2021
5 Closed-End Funds Bought In November
Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income
11:20am, Wednesday, 22'nd Sep 2021
Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income
Tekla Life Sciences Investors Declares Distribution
11:10am, Tuesday, 17'th Aug 2021
BOSTON--(BUSINESS WIRE)--On August 17, 2021, Tekla Life Sciences Investors declared a distribution of $0.43 per share. The record date for the stock distribution is August 27, 2021 and the payable dat
5 Dividend Funds Yielding Up To 27.2%
06:50pm, Sunday, 15'th Aug 2021
Double-digit dividends are rare. A sky-high yield of 27.2% is an outright income unicorn.
Evaluating Closed-End Funds: HQL Is Another Fine Pick In A Hot Sector
12:20pm, Tuesday, 29'th Jun 2021
As an income investor, the 7.8% yield is quite attractive to me if HQL can support it. I continue my series on CEFs looking beyond the yield.
Tekla Funds: In A World That Needs Healthcare, These Funds Have A Place In A Portfolio
09:27pm, Tuesday, 04'th May 2021
Healthcare offers essential services that people can't go without, recession or not. The Tekla funds can offer potential in any one of their funds for healthcare exposure.
Biotech Innovations Remain At Forefront
11:10am, Friday, 16'th Apr 2021
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r
Moving Beyond COVID In Biopharma
09:31am, Thursday, 15'th Apr 2021
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,
Tekla Life Sciences Investors: 8% Yield, 7% Discount
09:15am, Saturday, 09'th Jan 2021
HQL has outperformed other healthcare-oriented CEFs over the past year. It's selling at a -7.27% discount to NAV.
Tekla Life Sciences Investors Declares Cash Distribution
04:21pm, Monday, 21'st Dec 2020
BOSTON--(BUSINESS WIRE)--On December 21, 2020, Tekla Life Sciences Investors declared a special cash distribution of $0.02 per share in order to satisfy annual tax distribution requirements. The recor
The Best- And Worst-Performing CEFs YTD: October 2020
10:25am, Saturday, 10'th Oct 2020
We analyze performance trends in closed-end-funds this year along with themes by asset classes. Equity funds with concentrated exposure to Technology and Healthcare are among the biggest winners this
